Firebrick Pharma Limited (FRE.AX)
- Previous Close
0.0650 - Open
0.0650 - Bid 0.0620 x --
- Ask 0.0630 x --
- Day's Range
0.0620 - 0.0650 - 52 Week Range
0.0360 - 0.3600 - Volume
67,361 - Avg. Volume
280,085 - Market Cap (intraday)
11.117M - Beta (5Y Monthly) 1.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Firebrick Pharma Limited engages in the development and partnering of broad-spectrum antimicrobial spray for the treatment of common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
www.firebrickpharma.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Related News
Performance Overview: FRE.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FRE.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FRE.AX
Valuation Measures
Market Cap
11.12M
Enterprise Value
9.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.00
Price/Book (mrq)
6.99
Enterprise Value/Revenue
5.47
Enterprise Value/EBITDA
-2.13
Financial Highlights
Profitability and Income Statement
Profit Margin
-251.57%
Return on Assets (ttm)
-74.49%
Return on Equity (ttm)
-136.04%
Revenue (ttm)
1.82M
Net Income Avi to Common (ttm)
-4.57M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.31M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.14M
Company Insights: FRE.AX
FRE.AX does not have Company Insights